Oscient Pharma rated as outperform by JMP

JMP Securities has given Oscient Pharmaceuticals Corp. an outperform rating and set a price target at $3.00. Analyst Adam Culter noted that new prescriptions of antibiotic Factive were up to 4,114 this week from 3,993 the previous week.

Factive is used to treat illnesses such as pneumonia and sinusitis that occur more frequently in winter months, so prescriptions are likely to continue rising in the coming months.

Shares of the Waltham, Mass.-based biopharmaceutical company were down $0.01, or 0.56%, at $1.76 on volume of 543,085 shares versus the three-month running average of 752,600.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.